“Efficacy and Safety of Teclistamab Followed by Autologous Stem Cells Transplant in Functional High-Risk and Triple Class Refractory Multiple Myeloma”. 2025. Mediterranean Journal of Hematology and Infectious Diseases 17 (1): e2025051. https://doi.org/10.4084/MJHID.2025.051.